ES2545688T3 - Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide - Google Patents
Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide Download PDFInfo
- Publication number
- ES2545688T3 ES2545688T3 ES07818398.5T ES07818398T ES2545688T3 ES 2545688 T3 ES2545688 T3 ES 2545688T3 ES 07818398 T ES07818398 T ES 07818398T ES 2545688 T3 ES2545688 T3 ES 2545688T3
- Authority
- ES
- Spain
- Prior art keywords
- score
- methods
- risk
- disease progression
- rheumatoid arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract description 13
- 206010039073 rheumatoid arthritis Diseases 0.000 title abstract description 5
- 206010061818 Disease progression Diseases 0.000 title abstract description 4
- 230000005750 disease progression Effects 0.000 title abstract description 4
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 3
- 108010074051 C-Reactive Protein Proteins 0.000 abstract 2
- 102100032752 C-reactive protein Human genes 0.000 abstract 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 229940100601 interleukin-6 Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000007637 random forest analysis Methods 0.000 abstract 1
- 230000003628 erosive effect Effects 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 6
- 210000004247 hand Anatomy 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 5
- 210000000707 wrist Anatomy 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 102000013674 S-100 Human genes 0.000 description 4
- 108700021018 S100 Proteins 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 3
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 3
- 102100032442 Protein S100-A8 Human genes 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000008822 Ankylosis Diseases 0.000 description 2
- 206010051728 Bone erosion Diseases 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 206010023198 Joint ankylosis Diseases 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102100032420 Protein S100-A9 Human genes 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000511 carpometacarpal joint Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 210000001145 finger joint Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000001255 hallux Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 2
- 210000000878 metatarsophalangeal joint Anatomy 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WLSJJMZOYIFPGE-ICHHDKBFSA-N 1,1-difluoro-1-(beta-D-mannosyl)methyl C32-phosphonomycoketide Chemical compound CCCCCCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCCOP(C([C@@H]([C@H]([C@H]1O)O)O[C@H](CO)[C@H]1O)(F)F)(O)=O WLSJJMZOYIFPGE-ICHHDKBFSA-N 0.000 description 1
- IWZOWMVCZCJZJF-ZTZKFORPSA-N 5a-carba-beta-D-mannosyl C32-phosphomycoketide Chemical compound CCCCCCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCCOP(O)(O[C@H](C[C@H](CO)[C@H]([C@@H]1O)O)[C@H]1O)=O IWZOWMVCZCJZJF-ZTZKFORPSA-N 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000029892 regulation of protein phosphorylation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003189 scaphoid bone Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06020645 | 2006-09-29 | ||
| EP06020645 | 2006-09-29 | ||
| EP06021887 | 2006-10-19 | ||
| EP06021887 | 2006-10-19 | ||
| PCT/EP2007/008313 WO2008037420A1 (en) | 2006-09-29 | 2007-09-25 | Assessing the risk of disease progression for a patient with rheumatoid arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2545688T3 true ES2545688T3 (es) | 2015-09-15 |
Family
ID=38859738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07818398.5T Active ES2545688T3 (es) | 2006-09-29 | 2007-09-25 | Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8058013B2 (OSRAM) |
| EP (1) | EP2074428B1 (OSRAM) |
| JP (1) | JP2010506147A (OSRAM) |
| CA (1) | CA2663730A1 (OSRAM) |
| ES (1) | ES2545688T3 (OSRAM) |
| WO (1) | WO2008037420A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010038104A1 (en) * | 2008-10-03 | 2010-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event. |
| CA2777800C (en) | 2009-10-15 | 2019-11-12 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring inflammatory disease activity |
| US20130246097A1 (en) * | 2010-03-17 | 2013-09-19 | Howard M. Kenney | Medical Information Systems and Medical Data Processing Methods |
| WO2011129382A1 (en) * | 2010-04-16 | 2011-10-20 | Abbott Japan Co. Ltd. | Methods and reagents for diagnosing rheumatoid arthritis |
| WO2012012183A2 (en) * | 2010-06-30 | 2012-01-26 | New York University | Quantifying local inflammatory activity and its use to predict disease progression and tailor treatments |
| JP5924659B2 (ja) * | 2010-10-14 | 2016-05-25 | 国立大学法人 長崎大学 | 免疫複合体の網羅的解析方法および新規関節リウマチバイオマーカー |
| WO2012061821A1 (en) * | 2010-11-06 | 2012-05-10 | Crescendo Bioscience | Biomarkers for predicting progressive joint damage |
| US11531033B2 (en) * | 2013-03-15 | 2022-12-20 | Exagen Inc. | Methods for treating and diagnosing systemic lupus erythematosus |
| JP2015061592A (ja) * | 2013-08-21 | 2015-04-02 | コニカミノルタ株式会社 | 超音波診断装置、超音波画像処理方法およびコンピュータ読み取り可能な非一時的な記録媒体 |
| CA2943821A1 (en) | 2014-04-02 | 2015-10-08 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity |
| JP2017523437A (ja) | 2014-06-10 | 2017-08-17 | クレッシェンド バイオサイエンス インコーポレイテッド | 体軸性脊椎関節炎の疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法 |
| WO2017058999A2 (en) | 2015-09-29 | 2017-04-06 | Crescendo Bioscience | Biomarkers and methods for assessing response to inflammatory disease therapy withdrawal |
| JP6830105B2 (ja) | 2015-09-29 | 2021-02-17 | クレッシェンド バイオサイエンス インコーポレイテッド | 乾癬性関節炎の疾患活動性を評価するためのバイオマーカーおよび方法 |
| GB201603571D0 (en) * | 2016-03-01 | 2016-04-13 | Univ Warwick | Markers for skeletal disorders |
| EP4052044A1 (en) * | 2019-10-30 | 2022-09-07 | CD Diagnostics, Inc. | Biomarkers of early osteoarthritis |
| CN114089632B (zh) * | 2021-11-15 | 2023-08-18 | 陕西师范大学 | 基于模糊逻辑的风湿免疫疾病特征识别方法及系统 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105893D0 (en) | 1991-03-20 | 1991-05-08 | Orion Yhtymae Oy | Bone resorption assay based on a peptide liberated during collagen degradation |
| US5888510A (en) * | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| ATE199185T1 (de) | 1994-10-17 | 2001-02-15 | Osteometer Biotech As | Einschätzung der fragmentierungsmuster von kollagen in körperflüssigkeiten und diagnose von mit dem kollagenmetabolismus zusammenhängenden störungen |
| FR2752842B1 (fr) | 1996-08-30 | 1998-11-06 | Biomerieux Sa | Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide |
| NL1004539C2 (nl) | 1996-11-15 | 1998-05-20 | Stichting Tech Wetenschapp | Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen. |
| JP2002512939A (ja) | 1997-11-28 | 2002-05-08 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 診断および治療のためのツールとしての、リューマチ性関節炎の血清により認識されるシトルリン含有合成ペプチド |
| FR2773157B1 (fr) | 1997-12-30 | 2001-10-05 | Bio Merieux | Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide |
| NZ504683A (en) * | 1998-01-09 | 2002-06-28 | Pfizer | Amide derivatives and pharmaceutical compositions thereof and their use as matrix metalloprotease inhibitors |
| EP1240180A2 (en) | 1999-12-21 | 2002-09-18 | Innogenetics N.V. | Peptides designed for the diagnosis and treatment of rheumatoid arthritis |
| NL1019540C2 (nl) | 2001-12-11 | 2003-07-01 | Stichting Tech Wetenschapp | Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit. |
| EP1721163B1 (en) * | 2004-02-27 | 2015-04-29 | Roche Diagnostics GmbH | Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6 |
| US20060063162A1 (en) * | 2004-09-23 | 2006-03-23 | Deng David X | Biological marker for inflammation |
| WO2006098401A1 (ja) * | 2005-03-16 | 2006-09-21 | The University Of Tokushima | 関節リウマチ罹患リスクの測定方法 |
| CN101443357A (zh) * | 2005-08-12 | 2009-05-27 | 先灵公司 | Mcp1融合物 |
-
2007
- 2007-09-25 EP EP07818398.5A patent/EP2074428B1/en not_active Not-in-force
- 2007-09-25 ES ES07818398.5T patent/ES2545688T3/es active Active
- 2007-09-25 WO PCT/EP2007/008313 patent/WO2008037420A1/en not_active Ceased
- 2007-09-25 JP JP2009529589A patent/JP2010506147A/ja active Pending
- 2007-09-25 CA CA002663730A patent/CA2663730A1/en not_active Abandoned
-
2009
- 2009-03-27 US US12/412,840 patent/US8058013B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2663730A1 (en) | 2008-04-03 |
| US20090270272A1 (en) | 2009-10-29 |
| JP2010506147A (ja) | 2010-02-25 |
| US8058013B2 (en) | 2011-11-15 |
| EP2074428B1 (en) | 2015-07-01 |
| WO2008037420A1 (en) | 2008-04-03 |
| EP2074428A1 (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2545688T3 (es) | Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide | |
| Khella et al. | An evidence-based systematic review of human knee post-traumatic osteoarthritis (PTOA): timeline of clinical presentation and disease markers, comparison of knee joint PTOA models and early disease implications | |
| Tiku et al. | Cartilage regeneration for treatment of osteoarthritis: a paradigm for nonsurgical intervention | |
| Chen et al. | Osteoarthritis: toward a comprehensive understanding of pathological mechanism | |
| Stürmer et al. | Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein | |
| Woo et al. | Impact of osteoarthritis on quality of life in a Hong Kong Chinese population. | |
| Cuzdan Coskun et al. | Adiponectin: is it a biomarker for assessing the disease severity in knee osteoarthritis patients? | |
| Nwosu et al. | Pain prediction by serum biomarkers of bone turnover in people with knee osteoarthritis: an observational study of TRAcP5b and cathepsin K in OA | |
| Song et al. | Possible involvement of serum and synovial fluid resistin in knee osteoarthritis: cartilage damage, clinical, and radiological links | |
| Mason et al. | The first tarsometatarsal joint and its association with hallux valgus | |
| Clementi et al. | Efficacy of a single intra-articular injection of ultra-high molecular weight hyaluronic acid for hip osteoarthritis: a randomized controlled study | |
| O'Leary et al. | Characterization of facet joint cartilage properties in the human and interspecies comparisons | |
| Conte et al. | Endothelins modulate inflammatory reaction in zymosan-induced arthritis: participation of LTB4, TNF-α, and CXCL-1 | |
| Qin et al. | Expression of NF-κB and osteopontin of synovial fluid of patients with knee osteoarthritis | |
| Xu et al. | Contributions of joint damage-related events to gout pathogenesis: new insights from laboratory research | |
| Duan et al. | Infrapatellar fat pads participate in the development of knee osteoarthritis in obese patients via the activation of the NF‑κB signaling pathway | |
| Kamiab et al. | Role of Interleukin-17 family cytokines in disease severity of patients with knee osteoarthritis | |
| Jørgensen et al. | The regional turnover of cartilage collagen matrix in late-stage human knee osteoarthritis | |
| Lambrechts et al. | Comorbidities associated with cervical spine degenerative disc disease | |
| Chu et al. | Cartilage oligomeric matrix protein and matrix metalloproteinase-3 expression in the serum and joint fluid of a reversible osteoarthritis rabbit model | |
| Pan et al. | Elevation of serum CXC chemokine ligand-12 levels predicts poor outcome after aneurysmal subarachnoid hemorrhage | |
| Haider et al. | Plasma and synovial osteopontin levels, are they associated with disease severity of primary knee osteoarthritis in Egyptian patients? | |
| Tachikart et al. | Seno-suppressive molecules as new therapeutic perspectives in rheumatic diseases | |
| Abdel-Magied et al. | Diagnostic potential of ultrasound in systemic lupus erythematosus patients with joint involvement: relation to anticyclic citrullinated peptide (anti-CCP), disease activity and functional status | |
| Liu et al. | Endoplasmic reticulum stress-related protein GRP78 and CHOP levels in synovial fluid correlate with disease progression of primary knee osteoarthritis: A cross-sectional study. |